HitGen

Executive Summary

HitGen is a publicly traded drug discovery company based in Chengdu, China, that leverages its proprietary DNA-encoded library (DEL) technology and artificial intelligence/machine learning platforms to accelerate the identification of novel small molecule leads. Founded in 2012, the company has grown to over 500 employees and collaborates with pharmaceutical and biotechnology firms worldwide through research partnerships and licensing agreements. HitGen's platform aims to improve the efficiency and success rate of early-stage drug discovery, particularly in oncology, immunology, and infectious diseases. The company's core strength lies in its DEL technology, which enables the screening of billions of compounds, combined with AI/ML to analyze and prioritize hits, thereby reducing the time and cost of lead generation. As a platform company, HitGen generates revenue through upfront payments, milestones, and royalties from partnerships, positioning it as a key enabler in the global drug discovery ecosystem. HitGen's competitive advantage is rooted in its integration of DEL and AI, which is increasingly adopted by major pharma. The company has a track record of partnerships with leading pharmaceutical companies, and its public listing provides transparency and access to capital markets. However, its reliance on partnership-driven revenues and the highly competitive landscape in early-stage drug discovery present risks. The company's growth is contingent on expanding its partnership pipeline and advancing its internal discovery programs. With a strong intellectual property portfolio and a scalable platform, HitGen is well-positioned to capture value in the evolving drug discovery market. Upcoming catalysts include potential new partnerships, progress in internal pipeline programs, and technology platform enhancements.

Upcoming Catalysts (preview)

• Q3 2026Major Pharma Partnership Announcement70% success
• Q4 2026Advancement of Internal DEL-based Program into Preclinical Development50% success
• Q3 2026Publication or Presentation of AI-Enhanced DEL Hit Discovery Data80% success